Literature DB >> 23112064

FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan.

Ingrid Torjesen.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23112064     DOI： 10.1136/bmj.e7323

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus.

Authors:  Elliott M Groves; Katherine Yu; Nathan D Wong; Shaista Malik
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-11-15

2.  To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.

Authors:  Thomas Christian Kühler; Magda Bujar; Neil McAuslane; Lawrence Liberti
Journal:  BMJ Open       Date:  2019-11-25       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.